ApoB (Apolipoprotein B)
A direct count of atherogenic particles. Every LDL, VLDL, IDL and Lp(a) particle carries exactly one ApoB molecule — so ApoB tells you how many plaque-causing particles are circulating, not just how much cholesterol they carry.
Arguably the most important cardiovascular marker you can run, and newly recommended in the US dyslipidemia guideline. It outperforms LDL-C at predicting events — especially in people with metabolic syndrome, diabetes, high triglycerides, or deceptively 'normal' LDL-C.
Check a ApoB (Apolipoprotein B) result against this range →
What ApoB (Apolipoprotein B) actually measures — the analyte, and the assay
The analyte is apolipoprotein B, a 4,536-residue protein of roughly 550 kDa that wraps a lipoprotein particle once and never comes off. One particle, one apoB. That is not a convenient approximation, it is structural — and it is the entire reason this test is different in kind from the cholesterol numbers around it. LDL-C answers how much cholesterol is being carried. ApoB answers how many things are carrying it.
The measurement is an immunoturbidimetric or nephelometric assay: antibody is added, complexes scatter light, and the scatter is compared against an international reference preparation. Two features follow from that and both matter. First, it is a direct measurement — nothing is calculated from anything, unlike the LDL-C beside it. Second, because manufacturers calibrate to a common reference material, apoB transfers between laboratories better than almost any other lipid number on the panel.
It also does not need a fast. The joint European Atherosclerosis Society and European Federation of Clinical Chemistry consensus concluded that fasting is not routinely required for a lipid profile Nordestgaard 2016, and apoB is the member of the panel least disturbed by a recent meal, because eating adds cholesterol and triglyceride to particles without much changing how many particles there are.
What the assay counts, precisely: every LDL, VLDL, IDL and Lp(a) particle in the tube, each contributing exactly one molecule. In the fasting state that is about 90% LDL. It is a sum, and one of the limits further down this page follows from that.
ApoB (Apolipoprotein B): what changes the blood, and what only changes the reading
What changes the particle count in your blood — ranked:
- Genetics. Familial hypercholesterolemia and the common polygenic score both act on LDL receptor traffic, which sets how fast particles are removed. This is the largest single determinant in most people and it is present from birth.
- Lipid-lowering drugs. Statins, ezetimibe, bempedoic acid and PCSK9 inhibitors all work by increasing hepatic LDL receptor activity or reducing production, and they move apoB more reliably than anything else available.
- Insulin resistance and visceral fat. These raise VLDL particle secretion, which is why apoB and LDL-C separate most in exactly the metabolic phenotype where LDL-C looks reassuring Sniderman 2024.
- Dietary saturated fat, through the same receptor pathway.
- Hypothyroidism, which slows LDL receptor-mediated clearance and raises apoB — one of the few places where two panels on this site share a mechanism rather than a page.
- Androgens, particularly oral 17-alpha-alkylated compounds, which raise apoB while suppressing HDL.
- Nephrotic syndrome, cholestasis and pregnancy, each by a different route.
What changes only the reading — a short list, and that is the point of the marker:
- Severe lipemia. A turbidimetric assay measures scattered light, so a grossly turbid specimen can distort it; this is the same specimen problem that gets samples rejected outright at extreme triglyceride concentrations Van Elslande 2021.
- Paraproteins, which precipitate in some turbidimetric systems.
- An acute-phase state. Cholesterol and apoB fall for weeks after a myocardial infarction, major surgery or serious infection, so a value drawn in hospital understates the patient's usual concentration.
- Nothing much else. There is no biotin problem, no heterophile problem and no calculation to go wrong — which is precisely the argument for preferring it to an estimated LDL-C Sajja 2021.
Reference interval or decision threshold — which kind of number ApoB (Apolipoprotein B) is
Two different kinds of number get printed in the same box, and confusing them is the mistake this page exists to prevent.
The reference interval — the 52–109 mg/dL kind of figure — is the central 95% of whoever that laboratory measured. In a population where atherosclerosis is the leading cause of death, that interval describes what is common. It is not a claim that anything inside it is safe, and it is the only sense in which a population apoB is 'normal'.
The decision thresholds — the sub-70 and sub-65 kind of figure — are a different species entirely: they come from event rates in cohorts and from the trial evidence that lowering apoB lowers those rates. In 293,876 UK Biobank adults aged 40 to 73 followed to 19,982 new-onset atherosclerotic events, the analysis that matters was of discordance: what happens to risk when apoB and the cholesterol measures disagree Sniderman 2024. The same cohort has been used to show apoB outperforming even a direct LDL particle count Epstein 2025, and comparisons of apoB with LDL-C and non-HDL-C as risk markers keep landing in the same place Sehayek 2025.
So: the reference interval is distributional, the target is outcome-derived, and they disagree by a wide margin. A 105 mg/dL apoB is inside the reference interval and above every primary-prevention target published. Both statements are true and only one of them is about you. The same logic is now being extended past coronary disease — apoB and Lp(a) have been assessed for sex-specific aortic stenosis risk in the same biobank Shi 2026.
How you would know your ApoB (Apolipoprotein B) was wrong — and when to redraw
Six to eight weeks after any change, and the number comes from particle kinetics. An LDL particle's residence time in plasma is measured in days, so the pool reaches a new steady state within a few weeks of a change in production or clearance. Redraw at two weeks after starting a statin and you will see most of the effect; redraw at eight and you will see all of it, on a stable baseline.
Conditions that must match: the same laboratory; at least four to six weeks clear of any acute illness, injury or surgery; a stable weight, since an active deficit moves lipids independently of the intervention; and honesty about adherence, which is by far the commonest reason an apoB has not moved.
What would have to change for the retest to mean something. ApoB should move with non-HDL cholesterol. When the two travel together, the change is real; when they separate, that separation is itself the finding and it usually means the particles have changed composition — smaller, more cholesterol-depleted particles give a higher apoB for the same cholesterol Sniderman 2024. ApoB falling while non-HDL-C is flat, or the reverse, is the one pattern that should send you back to the laboratory rather than to a conclusion.
How you would know the value was wrong. A grossly discrepant apoB with an unremarkable full lipid panel, in a specimen described as lipemic, should be repeated on a properly fasted sample Van Elslande 2021. And a persistently high apoB with a normal-looking LDL-C is not evidence of an error — it is the single most useful result this test produces, and the confirmatory step is Lp(a), not a repeat.
What ApoB (Apolipoprotein B) cannot tell you
It cannot tell you what kind of particle you have too many of. The count sums LDL, VLDL, IDL and Lp(a). Two people with an apoB of 110 mg/dL can have completely different panels underneath it, and the clinical response differs.
It hides a high Lp(a). Every Lp(a) particle carries an apoB and is counted here, and Lp(a)-cholesterol has been shown to make up anywhere from 5.8% to 57.3% of what a laboratory reports as LDL cholesterol in people who have it Yeang 2021. ApoB does not flag which of its particles are the genetically determined, diet-resistant kind. That takes a separate test, once.
It measures exposure, not disease. ApoB describes how many atherogenic particles are circulating; it says nothing about how much plaque is already in an artery wall, which is a question for imaging. A low apoB at 55 does not mean clean arteries and a high one at 35 does not mean disease.
It cannot be read from a single draw in an acutely ill person, for the acute-phase reason above.
The wrong inference readers actually draw is the reverse of the usual one: a normal LDL-C alongside a high apoB is not normal risk. That combination — discordance — is common, it is concentrated in people with insulin resistance or high triglycerides, and it is the situation in which the cholesterol number systematically understates the particle burden Sniderman 2024. It is also the situation in which a calculated LDL-C is least reliable in the first place Sajja 2021.
Sources read for these sections
- Sniderman AD, et al. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. European Heart Journal 2024 · PMID 38700053
- Epstein E, et al. Apolipoprotein B outperforms low density lipoprotein particle number as a marker of cardiovascular risk in the UK Biobank. European Journal of Preventive Cardiology 2025 · PMID 40887080
- Sehayek D, et al. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk. Journal of Clinical Lipidology 2025 · PMID 40681368
- Nordestgaard BG, et al. Fasting is not routinely required for determination of a lipid profile. European Heart Journal 2016 · PMID 27122601
- Sajja A, et al. Comparison of Methods to Estimate Low-Density Lipoprotein Cholesterol in Patients With High Triglyceride Levels. JAMA Network Open 2021 · PMID 34709388
- Yeang C, et al. Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. Journal of Lipid Research 2021 · PMID 33636163
- Shi W, et al. Moving beyond Low-Density Lipoprotein cholesterol: apolipoprotein B and Lipoprotein (a) for sex-specific risk assessment of aortic stenosis in the UK Biobank. European Journal of Preventive Cardiology 2026 · PMID 42104638
The plan of attack
In this order. Most people start at step four, which is why they change five things at once and learn nothing.
- Confirm the number is real
Fasting state. Less affected by eating than a calculated LDL, which is one of its advantages — but it still shifts modestly. Fasted is preferable; consistency matters more. - Read it with its partner
Non-fasting is acceptable for ApoB. It's the marker to watch if you plan to be on hormones for decades. Draw it alongside: Lipoprotein(a) — Lp(a), Lipid Panel (Cholesterol, HDL, LDL, Triglycerides), hs-CRP (High-Sensitivity C-Reactive Protein). - Work out which direction is yours
If it's high — Increased atherosclerotic risk that compounds over years. Silent until it isn't. - Fix it in this order
Nutrition. Reduce saturated fat (the single biggest dietary lever on ApoB), increase soluble fiber (oats, psyllium, beans), add plant sterols, lose visceral fat, and replace saturated with mono/polyunsaturated fats.
Lifestyle. Aerobic exercise, fat loss, smoking cessation, alcohol moderation.
Supplements. Psyllium husk (~5–10% LDL reduction), plant sterols/stanols, berberine (meaningful LDL/ApoB reduction in trials), red yeast rice (contains natural monacolin K — same mechanism as a statin, so treat it like one), omega-3s primarily for triglycerides.
Hormones. Statins, ezetimibe, bempedoic acid, PCSK9 inhibitors are the evidence-based tools and are extremely effective. If you're a lifelong optimizer using androgens, treating ApoB pharmacologically is often the rational trade — discuss with a physician. Correct hypothyroidism, which raises ApoB.
Compounds. Anyone on TRT or AAS should be tracking ApoB, not just a standard lipid panel. Androgens — particularly orals — suppress HDL and raise ApoB. This marker tracks the actual long-term cost of your protocol.
Work down the list, not across it. Adding a compound on top of an unfixed diet is why generic protocols fail. - Retest
Every 3–6 months on androgens or after any intervention; annually otherwise. Change one thing at a time, or the retest can't tell you which thing worked.
How to fix it
📚 2026 AHA/ACC Guideline on the Management of Dyslipidemia — ApoB introduced as recommended measurement. Sniderman AD et al., JAMA Cardiol 2019 — ApoB vs LDL-C discordance.
This page can tell you what could have made your ApoB (Apolipoprotein B) wrong. It cannot tell you whether it did.
Everything above is free and stays free — the assay, what changes the reading rather than the blood, the retest window and the sources. What no page can do is look at your draw: which laboratory ran it, at what hour, what you were taking that week, and what else was flagged beside it. Every one of those changes the answer, and none of them is on any page. Bringing a real result to people who know that list is what the members' area is for.
Bring your result — $10/mo →🩸 Test your ApoB (Apolipoprotein B)
Order directly through Marek Diagnostics — no doctor's visit needed, drawn at any Quest location in the US. Code CAMERON applies 10% off automatically.
Order this test — 10% off → Browse all 103 markers →What ApoB (Apolipoprotein B) is usually tested alongside
One marker is a data point. These panels add the markers that make ApoB (Apolipoprotein B) interpretable, name why each is on the list, and load the set into your cart at 10% off.
includes this + 9 more markers — Anyone eating ketogenic, carnivore or seriously low-carbohydrate — especially anyone whose LDL cholesterol went up sharply after starting, and anyone who feels cold, flat or is losing training performance months in.
includes this + 8 more markers — Taking rapamycin off-label on a weekly or intermittent longevity protocol. This panel exists because the compound is being used outside the setting its evidence comes from, and almost everything that matters about it is measurable.
What people use ApoB (Apolipoprotein B) to decide
Nobody orders a test for its own sake. ApoB (Apolipoprotein B) is on the test list for these pathways — each one links to what the pathway claims, and what its test list is read for before you spend anything on it.
ApoB counts atherogenic particles; LDL-C estimates the cholesterol inside them. When the two disagree — common in insulin resistance — ApoB is right and LDL-C is falsely reassuring.
The brain is 20% of resting energy use, and cerebral perfusion follows the same vascular rules as the heart. Raised ApoB and HbA1c predict cognitive decline decades ahead — this is the most actionable pathway here and the least exciting.
These are the numbers with real causal mortality evidence. ApoB beats LDL-C, Lp(a) is genetic and worth measuring exactly once in your life, and cystatin-C catches kidney decline that creatinine misses. If you test nothing else on this page, test these.
Erectile dysfunction is an early cardiovascular symptom — the penile arteries are narrower than the coronaries and narrow first, typically three to five years ahead. Treat this as a heart finding, because it is one.
ApoB (Apolipoprotein B) is also on the test list for these, where it narrows the picture rather than settling it:
What moves your ApoB (Apolipoprotein B)
4 supplements in the Vault have a documented effect on this marker, or are a reason to have measured it first:
Browse all 278 compounds & 371 supplements →
Would you feel it? Symptoms ApoB (Apolipoprotein B) helps explain
People search for how they feel, not for a marker. These are the complaints where this one is worth checking, and whether it is first-line or a follow-up.
Why your ApoB (Apolipoprotein B) might be wrong
Most abnormal results are interference, not disease. Check these before you change anything. Each says whether the number is wrong (repeat it), badly timed (redraw it), or real with a cause.
Less affected by eating than a calculated LDL, which is one of its advantages — but it still shifts modestly.
Fasted is preferable; consistency matters more.
ApoB falls during acute illness along with the rest of the lipid panel, so a post-admission draw understates your true particle count.
Wait six weeks after anything significant.
All lower ApoB, which is the point. The interference is in interpretation — a good ApoB on treatment is not the same as a good untreated one.
Record what you were taking at each draw.
What ApoB (Apolipoprotein B) means in combination
One marker tells you a little; combinations tell you the story. These are the named patterns this one takes part in.
The single most under-monitored consequence of androgen use. Androgens — especially oral 17-alpha-alkylated compounds — suppress HDL dramatically and raise ApoB. There are no symptoms; the cost is cumulative arterial damage measured in decades.
Prefer injectables over orals and minimize oral duration. Add cardio, soluble fiber, omega-3s. Many long-term users treat ApoB pharmacologically (statin/ezetimibe) with a physician — that's a rational trade if you're committed to being on hormones for years. Track ApoB every 3 months, not just a standard lipid panel.
Lp(a) is almost entirely genetic, largely unmoved by diet, and independently raises cardiovascular and aortic valve risk. A normal LDL alongside it is falsely reassuring.
Measure it once — it barely changes over a lifetime. You cannot lower it much yet, so the response is to drive everything else down hard: ApoB, blood pressure, insulin resistance, smoking. Tell your first-degree relatives to test theirs.
Residual inflammatory risk. Plaque forms and destabilizes through inflammation as well as lipids, so hitting an ApoB target while CRP stays high leaves a meaningful part of the risk untouched.
Rule out the obvious first — CRP rises with any infection, injury or hard training, so retest rested and well. If it stays up: sleep, visceral fat, periodontal disease, gut health, omega-3s. Persistent unexplained elevation deserves a real workup.
What to test next
These put ApoB (Apolipoprotein B) in context — each with its own full breakdown.
Frequently asked questions
52–109 mg/dL (population distribution — not a health target). Ranges vary by laboratory and assay — always compare to the range printed on your own report.
<70 mg/dL for primary prevention; <55–65 mg/dL if higher risk. Plaque regression has been observed on coronary CT below 70. Population 'normal' is emphatically not optimal.
Increased atherosclerotic risk that compounds over years. Silent until it isn't.
Favorable. Very low values are usually genetic and generally benign.
You can order ApoB (Apolipoprotein B) directly through Marek Diagnostics without a doctor's visit — drawn at any Quest Diagnostics location in the US. Code CAMERON applies 10% off automatically.
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.